These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
543 related articles for article (PubMed ID: 24816809)
1. Prasugrel plus bivalirudin vs. clopidogrel plus heparin in patients with ST-segment elevation myocardial infarction. Schulz S; Richardt G; Laugwitz KL; Morath T; Neudecker J; Hoppmann P; Mehran R; Gershlick AH; Tölg R; Anette Fiedler K; Abdel-Wahab M; Kufner S; Schneider S; Schunkert H; Ibrahim T; Mehilli J; Kastrati A; Eur Heart J; 2014 Sep; 35(34):2285-94. PubMed ID: 24816809 [TBL] [Abstract][Full Text] [Related]
2. Comparison of prasugrel and bivalirudin vs clopidogrel and heparin in patients with ST-segment elevation myocardial infarction: Design and rationale of the Bavarian Reperfusion Alternatives Evaluation (BRAVE) 4 trial. Schulz S; Richardt G; Laugwitz KL; Mehran R; Gershlick AH; Morath T; Mayer K; Neudecker J; Tölg R; Ibrahim T; Hauschke D; Braun D; Schunkert H; Kastrati A; Mehilli J; Clin Cardiol; 2014 May; 37(5):270-6. PubMed ID: 24633823 [TBL] [Abstract][Full Text] [Related]
3. Influence of timing of clopidogrel treatment on the efficacy and safety of bivalirudin in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention: an analysis of the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. Lincoff AM; Steinhubl SR; Manoukian SV; Chew D; Pollack CV; Feit F; Ware JH; Bertrand ME; Ohman EM; Desmet W; Cox DA; Mehran R; Stone GW; JACC Cardiovasc Interv; 2008 Dec; 1(6):639-48. PubMed ID: 19463378 [TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials. Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052 [TBL] [Abstract][Full Text] [Related]
5. Platelet function and coagulation in patients with STEMI and peri-interventional clopidogrel plus heparin vs. prasugrel plus bivalirudin therapy (BRAVE 4 substudy). Braun D; Knipper A; Orban M; Sibbing D; Petzold T; Braun S; Schulz S; Hausleiter J; Kastrati A; Mehilli J; Massberg S Thromb Res; 2016 Jan; 137():72-78. PubMed ID: 26639204 [TBL] [Abstract][Full Text] [Related]
6. A comparative study of bivalirudin plus clopidogrel versus bivalirudin plus prasugrel in primary angioplasty using propensity score matching. Díaz DE LA Llera LS; Cubero Gómez JM; Rangel D; Parejo J; Acosta J; Fernández-Cisnal A; Zafra F; Benezet J J Interv Cardiol; 2013 Oct; 26(5):463-9. PubMed ID: 23952746 [TBL] [Abstract][Full Text] [Related]
7. Outcomes in patients with ST-segment elevation acute myocardial infarction treated with clopidogrel versus prasugrel (from the INFUSE-AMI trial). Brener SJ; Oldroyd KG; Maehara A; El-Omar M; Witzenbichler B; Xu K; Mehran R; Gibson CM; Stone GW Am J Cardiol; 2014 May; 113(9):1457-60. PubMed ID: 24630789 [TBL] [Abstract][Full Text] [Related]
8. [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010]. Silber S Herz; 2010 Dec; 35(8):558-64. PubMed ID: 21107514 [TBL] [Abstract][Full Text] [Related]
9. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P; Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988 [TBL] [Abstract][Full Text] [Related]
10. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial. Moliterno DJ; Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of bivalirudin in patients receiving clopidogrel therapy after diagnostic angiography for percutaneous coronary intervention in acute coronary syndromes. Feldman DN; Minutello RM; Bergman G; Moussa I; Wong SC Catheter Cardiovasc Interv; 2010 Oct; 76(4):513-24. PubMed ID: 20882655 [TBL] [Abstract][Full Text] [Related]
12. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. Dangas G; Mehran R; Guagliumi G; Caixeta A; Witzenbichler B; Aoki J; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Rabbani LE; Parise H; Stone GW; J Am Coll Cardiol; 2009 Oct; 54(15):1438-46. PubMed ID: 19796737 [TBL] [Abstract][Full Text] [Related]
13. Improving outcomes with bivalirudin in primary percutaneous coronary intervention. Stone GW Eur Heart J; 2014 Sep; 35(34):2269-72. PubMed ID: 24872459 [No Abstract] [Full Text] [Related]
14. MULTInational non-interventional study of patients with ST-segment elevation myocardial infarction treated with PRimary Angioplasty and Concomitant use of upstream antiplatelet therapy with prasugrel or clopidogrel--the European MULTIPRAC Registry. Clemmensen P; Grieco N; Ince H; Danchin N; Goedicke J; Ramos Y; Schmitt J; Goldstein P; Eur Heart J Acute Cardiovasc Care; 2015 Jun; 4(3):220-9. PubMed ID: 25182465 [TBL] [Abstract][Full Text] [Related]
15. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction). Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919 [TBL] [Abstract][Full Text] [Related]
16. Utilization of anticoagulants and outcomes in STEMI patients undergoing PPCI in the US hospitals: Bivalirudin, heparin plus GPI or heparin alone? Plent S; Mitchell M; Fan W; Werner R Hosp Pract (1995); 2015; 43(3):164-71. PubMed ID: 26190670 [TBL] [Abstract][Full Text] [Related]
17. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). Udell JA; Braunwald E; Antman EM; Murphy SA; Montalescot G; Wiviott SD JACC Cardiovasc Interv; 2014 Jun; 7(6):604-12. PubMed ID: 24947719 [TBL] [Abstract][Full Text] [Related]
18. Improving adjunctive pharmacotherapy for primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: beyond the HORIZONS-AMI trial. Kereiakes DJ Rev Cardiovasc Med; 2009; 10(2):72-82. PubMed ID: 19593319 [TBL] [Abstract][Full Text] [Related]